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ABSTRACT (233 words) 
Breast adenoid cystic carcinoma (AdCC), a rare type of triple-negative breast cancer (TNBC), 
has been shown to be driven by MYB pathway activation, most often underpinned by the MYB-
NFIB fusion gene. Alternative genetic mechanisms, such as MYBL1 rearrangements, have been 
reported in MYB-NFIB-negative salivary gland AdCCs. Here we report on the molecular 
characterization by massively parallel sequencing of four breast AdCCs lacking the MYB-NFIB 
fusion gene. In two cases, we identified MYBL1 rearrangements (MYBL1-ACTN1 and MYBL1-
NFIB), which were associated with MYBL1 overexpression. A third AdCC harbored a high-level 
MYB gene amplification, which resulted in MYB overexpression at the mRNA and protein levels. 
RNA-sequencing and whole-genome sequencing revealed no definite alternative driver in the 
fourth AdCC studied, despite high levels of MYB expression and the activation of pathways 
similar to those activated in MYB-NFIB-positive AdCCs. In this case, a deletion encompassing 
the last intron and part of exon 15 of MYB, including the binding site of ERG-1, a transcription 
factor that may down-regulate MYB, and the exon 15 splice site, was detected. In conclusion, we 
demonstrate that MYBL1 rearrangements and MYB amplification likely constitute alternative 
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genetic drivers of breast AdCCs, functioning through MYBL1 or MYB overexpression. These 
observations emphasize that breast AdCCs likely constitute a convergent phenotype, whereby 
activation of MYB/MYBL1 and their downstream targets can be driven by the MYB-NFIB fusion 
gene, MYBL1 rearrangements, MYB amplification or other yet to be identified mechanisms. 
 
Key words: adenoid cystic carcinoma, breast, MYB, MYBL1, MYB-NFIB fusion gene 
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INTRODUCTION  
Breast adenoid cystic carcinoma (AdCC) is a rare type of triple-negative breast cancer (TNBC, 
i.e. estrogen receptor (ER), progesterone receptor (PR) and HER2-negative) [1,2]. Whilst 
differing from conventional TNBCs [1,3], breast AdCCs share with salivary gland AdCCs similar 
molecular profiles and an identical genetic driver: the MYB-NFIB fusion gene [1,3-7], which 
functions through MYB overexpression due to the loss of miRNA binding sites or super-enhancer 
translocations [5,8].  
 
Salivary gland AdCCs lacking the MYB-NFIB fusion gene may harbor MYBL1 
rearrangements [9-11]. MYBL1 encodes for the A-MYB protein, which shares with c-
MYB (encoded by MYB) extensive homology and downstream target genes, converging in the 
activation of similar downstream pathways. Consistent with this notion, salivary gland AdCCs 
harboring either rearrangements display similar transcriptomic profiles [11].  
 
Here we performed a comprehensive genomic analysis of four MYB-NFIB-negative breast 
AdCCs, indicating that MYBL1 rearrangements and MYB gene amplification likely constitute 
alternative oncogenic drivers of this rare form of TNBC. 
 
MATERIAL AND METHODS 
Case selection 
Four MYB-NFIB-negative breast AdCCs (Figure 1, supplementary material, Table S1) were 
retrieved from the authors’ institutions and centrally reviewed (supplementary material, 
Supplementary material and methods). Whole-exome sequencing (WES) data from AdCC11 and 
AdCC12 and three MYB-NFIB-positive AdCC controls were reported  previously [3]. Patient 
consent was obtained where appropriate, according to the protocols approved by the local 
Institutional Review Boards. 
 
Immunohistochemistry  
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Immunohistochemistry for ER, PR, HER2 and c-MYB (clone EP769Y) was performed as 
previously described [2,3,7] (supplementary material, Supplementary materials and methods, 
and Table S2).  
 
Microdissection and nucleic acid extraction  
DNA and/or RNA samples of AdCC11 and AdCC12, and of MYB-NFIB-positive controls were 
extracted from fresh-frozen tissue as previously described [3,12]; those of AdCC34 and AdCC35 
were retrieved from formalin-fixed paraffin-embedded tissue samples, following microdissection 
(supplementary material, Supplementary materials and methods).  
 
Whole-genome and targeted capture massively parallel sequencing 
Tumor-normal DNA samples of AdCC11 and AdCC12 were subjected to whole-genome 
sequencing (WGS), and those of AdCC34 to Memorial Sloan Kettering-Integrated Mutation 
Profiling of Actionable Cancer Targets (MSK-IMPACT) assay [12,13], which targets the entire 
coding regions of 410 cancer genes [12,13] (supplementary material, Supplementary materials 
and methods, and Table S3). Sequencing data analyses were performed as previously 
described (supplementary material, Supplementary materials and methods). To validate the 
somatic mutations identified by WGS, a re-analysis of the previously reported WES results [3] 
revealed a validation rate >90% (supplementary material, Supplementary materials and 
methods). WGS and MSK-IMPACT data have been deposited in the NCBI Sequence Read 
Archive under Accession Nos. SRP108137 and SRP108155, respectively. 
 
RNA-sequencing 
RNA-sequencing of AdCC11, AdCC12 and AdCC35, and of the MYB-NFIB-positive AdCC5 was 
performed to identify fusion transcripts [14] (supplementary material, Supplementary materials 
and methods). RNA-sequencing data have been deposited in the NCBI Sequence Read Archive 
under Accession No. SRP108156. 
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Fluorescence in situ hybridization (FISH) 
The MYB-NFIB fusion gene and MYBL1 rearrangements were evaluated by FISH in all cases as 
previously described [2] (supplementary material, Supplementary materials and methods).   
 
RT-qPCR 
RT-qPCR was performed to compare the expression levels of the 5′ and 3′ portions/exons of 
MYB and MYBL1 using TaqMan Assay-on-Demand, as described  previously [3], in all cases, 
MYB-NFIB-positive AdCC6 and AdCC8 [3], and three breast cancer cell lines with known MYB 
mRNA levels (supplementary material, Supplementary materials and methods).  
 
Gene set enrichment analysis (GSEA) 
Expression levels using normalized RNA-sequencing RPKM values were used for single sample 
GSEA (ssGSEA; https://genepattern.broadinstitute.org/gp/, supplementary material, 
Supplementary materials and methods).  
 
RESULTS AND DISCUSSION 
Histopathological characteristics of MYB-NFIB-negative breast AdCCs 
The four FISH-proven MYB-NFIB-negative AdCCs were of triple-negative phenotype and did not 
differ histologically from MYB-NFIB-positive AdCCs (Figure 1, supplementary material, Figure 
S1). c-MYB protein expression, which has been documented in AdCCs lacking the MYB-NFIB 
fusion gene [15], was detected at varying levels (AdCC35, H-score 43; AdCC12, H-score 75; 
AdCC34, H-score 120) in all cases but AdCC11 (Figure 1, supplementary material, Figure S2).  
 
AdCC35 harbors a MYBL1-NFIB fusion gene and MYBL1 overexpression 
RNA-sequencing of AdCC35 revealed an in-frame MYBL1-NFIB fusion gene, resulting in a 
chimeric transcript composed of exons 1-14 of MYBL1 and exon 9 of NFIB (Figure 2A). Both 
DNA binding and c-terminal regulatory domains of MYBL1 were retained, akin to previously 
reported MYB or MYBL1 rearrangements [10,11,16]. FISH analysis with MYBL1 break-apart 
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probes confirmed the MYBL1 rearrangement at the genomic level (Figure 1A), and RT-qPCR 
and RNA-sequencing revealed differential mRNA levels of the 5’ and 3’ portions of MYBL1, 
consistent with gene breakage (Figure 3A-B). MYBL1 was overexpressed as compared to MYB-
NFIB-positive AdCCs [3] and the breast cancer cell lines tested, and MYB expression was 
low (Figure 3A-B). As in a previously described MYBL1-rearranged salivary gland AdCC [9], c-
MYB protein expression was observed (Figure 1A, supplementary material, Figure S2A), 
potentially caused by the cross-reactivity between the c-MYB antibody and the rearranged A-
MYB protein, due to the extensive homology between MYB and MYBL1 genes and their 
respective proteins. 
 
AdCC11 harbors a MYBL1-ACTN1 fusion gene and MYBL1 overexpression  
WGS of AdCC11 revealed a low mutational burden (0.52/Mb) and a lack of TP53 mutations, 
which are frequently found in TNBCs [17] (Figure 4A, supplementary material, Table S4). RNA-
sequencing of this case resulted in the identification of an in-frame MYBL1-ACTN1 fusion gene, 
which comprised exons 1-8 of MYBL1 and exons 10-21 of ACTN1, resulting in loss of the C-
terminal regulatory domain of A-MYB (Figure 2B). MYBL1 rearrangements in salivary gland 
AdCCs have been described to occur with multiple partners [10,11], but ACTN1 has not been 
previously reported in this context. Consistent with these findings, FISH validated the MYBL1 
rearrangement (Figure 1B), and RT-qPCR and RNA-sequencing analyses showed high 
expression levels of the 5’ of MYBL1 and low levels of MYB.  
 
AdCC34 harbors MYB gene amplification and MYB overexpression 
AdCC34, which expressed c-MYB protein and lacked MYB-NFIB fusion gene and MYBL1 
rearrangements by FISH (Figure 1C, supplementary material, Figure S2B), was subjected to 
MSK-IMPACT, revealing only one synonymous mutation affecting TSC2 (E392E; supplementary 
material, Table S4) and a simple copy number profile. Importantly, however, AdCC34 harbored a 
focal amplification on 6q23.3 encompassing MYB (Figure 4B). This was confirmed by FISH 
(mean of 5 (range 3-10) copies of MYB per tumor cell; Figure 1C), and found to be associated 
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with high MYB mRNA (Figure 3A-B) and MYB protein expression levels (supplementary material, 
Figure S2B). MYB amplification has not been previously described in AdCCs of any anatomical 
site. Based on the lack of potentially pathogenic somatic mutations and of MYB and MYBL1 
rearrangements, it is plausible that MYB overexpression was the result of MYB gene 
amplification, a novel potential mechanism of MYB activation in breast AdCCs.  
 
AdCC12 expresses MYB and displays a gene expression profile consistent with 
MYB/MYBL1 activation, despite the lack of MYB and MYBL1 rearrangements  
RNA-sequencing, WGS and FISH of AdCC12 revealed no fusion genes or copy number 
alterations affecting MYB, MYBL1 or other potential candidates (Figure 1D, Figure 4C). MYB 
overexpression was, however, identified by immunohistochemistry (Figure 1, supplementary 
material, Figure S2C), RT-qPCR (Figure 3A) and RNA-seq (Figure 3B). ssGSEA revealed that 
AdCC12 shared with MYBL1-rearranged AdCC35 and AdCC11 and the MYB-NFIB-positive 
AdCC5 similar transcriptomic profiles enriched for the MYC and NOTCH signaling 
pathways (Figure 3C). These findings suggest that MYB activation may be driven by yet 
additional genetic mechanisms.  
 
WGS analysis revealed a low mutational burden (0.73/Mb). We identified, however, a large 
deletion mapping to the last intron and part of exon 15 of MYB (c.2170-1153_2218), 
encompassing the binding sites of the transcription factors ERG-1 and VDR, a DNase I 
hypersensitive site and the initial parts of exon 15, including the splice site (supplementary 
material, Figure S3 and Table S4). Up-regulation of ERG-1 has been shown to result in down-
regulation of MYB [18], hence loss of its binding site could have potentially resulted in MYB 
overexpression. In addition, this large deletion could account for the higher mRNA levels of the 5’ 
part than the 3’ part of MYB (Figures 3A and 3B). We have also identified an intronic single-
nucleotide deletion within intron 1 of MYBL2 (Figure 4C; supplementary material, Table S4), 
affecting a locus between the promoter and promoter flanking regions (c.20+1403delG). MYBL2, 
which was highly expressed in AdCC12 (supplementary material, Figure S4) and has been 
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implicated in the biology of different human malignancies by regulating cell cycle and 
proliferation [19], is the third member of the MYB-family genes, encoding the B-MYB protein. B-
MYB, however, is less closely related to either c-MYB or A-MYB than the latter two are related 
between themselves. Given that the functional impact of non-coding variants has been 
increasingly recognized in cancer [20], further studies are warranted to investigate whether these 
MYB and/or MYBL2 alterations would be pathogenic and activate the MYB pathway akin to MYB 
or MYBL1 rearrangements.  
 
Taken together, we have identified MYBL1 rearrangements and MYB amplification as alternative 
genetic drivers of MYB-NFIB-negative breast AdCCs. Our analysis corroborates the previous 
findings of MYB and MYBL1 rearrangements causing overexpression of MYB and MYBL1, 
respectively, whereas a subset of AdCCs lack MYB/MYBL1 rearrangements but still display 
relatively high mRNA levels of either gene and activation of similar pathways. Moreover, we 
demonstrate that not only rearrangements, but also gene amplification may be the genetic 
alteration resulting in MYB overexpression in breast AdCCs. 
 
Our study has important limitations. The number of cases analyzed is small because breast 
MYB-NFIB-negative AdCCs are vanishingly rare. Owing to limited amount of tissue, we could 
only perform a targeted massively parallel sequencing assay in AdCC34, which does not rule out 
the possibility of co-existing fusion genes. Despite these limitations, our data support the 
contention that MYB/MYBL1 activation likely constitutes the common mechanism driving breast 
AdCCs, to which various underlying genomic alterations may converge. Further investigation of 
larger cohorts of AdCCs lacking the MYB-NFIB fusion gene, MYBL1 rearrangements and MYB 
gene amplification are warranted to elucidate the drivers of AdCCs lacking these genetic 
alterations. 
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FIGURE LEGENDS 
Figure 1. Histologic and immunohistochemical features and MYB/MYBL1 fluorescence in 
situ hybridization results of four breast adenoid cystic carcinomas (AdCCs). 
Representative micrographs depicting histologic features (magnification 200X), c-MYB 
immunohistochemistry (magnification 200X), MYB-NFIB three-color FISH (green: 5’ MYB, 
orange: 3’ MYB, red: 3’ NFIB) and MYBL1 dual-color break-apart FISH (green: 5’ MYBL1, red: 3’ 
MYBL1) of four MYB-NFIB-negative breast AdCCs. (A) AdCC35, displaying c-MYB expression, 
and rearrangement of MYBL1 as demonstrated by a single green 5’ signal (arrowhead) and loss 
of the red 3’ signal, indicative of an unbalanced translocation. (B) AdCC11, lacking c-MYB 
protein expression and displaying rearrangement of MYBL1 as demonstrated by a break-apart 
signal pattern of MYBL1 by FISH (arrowheads). (C) AdCC34, displaying c-MYB protein 
expression and MYB DNA amplification indicated by multiple green/orange signals in the form of 
small clusters, with an average of 5 MYB signals per cell), whereas ~2 copies were observed for 
NFIB (red). (D) AdCC12, displaying c-MYB protein expression and no altered signal patterns in 
MYB-NFIB and MYBL1 FISH. FISH, fluorescence in situ hybridization; H&E, hematoxylin & eosin; 
IHC, immunohistochemistry. Note that the same H&E micrograph of AdCC12 is also depicted in 
supplementary material, Figure S1. 
 
Figure 2. MYBL1 rearrangements identified by RNA-sequencing in two breast adenoid 
cystic carcinomas (AdCCs). 
MYBL1 fusion transcripts are illustrated, including the exons and domains involved. The 
breakpoints of each 5’ (MYBL1) and 3’ partner genes are represented as black lines. (A) 
AdCC35, displaying a MYBL1-NFIB fusion transcript, in which the c-terminal negative regulatory 
domain is retained, creating a ‘long’ fusion transcript as described by Mitani et al. in salivary 
gland AdCCs [10]. (B) AdCC11, displaying a MYBL1-ACTN1 fusion transcript, in which the c-
terminal negative regulatory domain is lost, creating a ‘short’ fusion transcript. DBD, DNA binding 
domain; NRD; negative regulatory domain; TAD, transactivation domain. 
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Figure 3. MYB and MYBL1 gene expression levels in breast adenoid cystic carcinomas 
(AdCCs) defined by RT-qPCR and RNA-sequencing. 
(A, B) The gene expression levels of the 5’ and 3’ portions of the MYBL1 (left) and MYB (right) 
transcripts in four MYB-NFIB-negative breast AdCCs are compared to those of AdCCs 
previously documented to harbor the MYB-NFIB fusion gene (AdCC5, AdCC6 and/or AdCC8) 
[1,3] and/or three breast cancer cell lines (T47D, HCC38 and Hs578T), as defined by RT-qPCR 
(A), error bars, SD of mean (n = 3 experimental replicates); (B), RNA-sequencing using 
normalized RPKM values). (C) Single sample gene set enrichment analysis (ssGSEA) was 
performed to assess pathways activated in the four breast AdCCs analyzed by RNA-sequencing. 
The calculated enrichment score (ES) for each pathway in each case is illustrated, where each 
column represents a case and each line represents a pathway. For comparison, the MYB-NFIB-
positive AdCC5 [3] was included. Amp, amplification, RPKM, reads per kilobase per million 
mapped reads. 
 
Figure 4. Genomic and transcriptomic features of the MYB-NFIB-negative breast adenoid 
cystic carcinomas AdCC11, AdCC12 and AdCC34. 
(A) Circos plot of AdCC11 depicting the chromosomes on the outer ring, the non-synonymous 
somatic mutations, copy number alterations and the fusion genes in the center. The MYBL1-
ACTN1 fusion gene is illustrated in blue, and likely-pathogenic mutations in red. (B) Copy 
number plot of AdCC34, depicting amplification of 6q23.3, encompassing the MYB gene. The 
Log2 ratios are plotted along the y-axis and the chromosome positions are plotted along the x-
axis. (C) Circos plot of AdCC12 depicting the chromosomes on the outer ring, the non-
synonymous somatic mutations, copy number alterations and the fusion genes in the center. 
Likely-pathogenic mutations are shown in red. The MYB large deletion and the MYBL2 mutation 
identified are also shown.   
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Figure S1. Histologic features of the MYB-NFIB-negative breast adenoid cystic carcinomas 
included in this study 
Figure S2. c-MYB protein expression in MYB-NFIB-negative adenoid cystic carcinomas as 
defined by immunohistochemistry 
Figure S3. Copy number plot of the MYB gene locus in AdCC12 
Figure S4. MYBL2 gene expression in adenoid cystic carcinomas as defined by RNA-
sequencing 
Table S1. Clinico-pathologic characteristics of four breast adenoid cystic carcinomas included in 
this study 
Table S2. List of antibodies, clones, dilutions, antigen retrieval methods and scoring systems 
Table S3. Sequencing statistics of whole-genome sequencing (WGS) and targeted massively 
parallel sequencing (MSK-IMPACT) analyses performed 
Table S4. List of somatic mutations identified by whole-genome sequencing (AdCC11, AdCC12; 
mutations affecting exonic and selected intronic regions are shown) or by targeted massively 
parallel sequencing (MSK-IMPACT; AdCC34) 
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